risperidone and Claustrophobia studies

Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.

Research Excerpts

Excerpt	Relevance	Reference
"Thirty patients with a primary diagnosis of an anxiety disorder-panic disorder (PD), social anxiety disorder (SAD), or generalized anxiety disorder (GAD)-refractory to initial pharmacotherapy with an adequate (or maximally tolerated) antidepressant and/or benzodiazepine trial of at least 8 weeks' duration prior to study initiation received open-label augmentation with flexibly dosed risperidone for 8 weeks."	9.12	An open-label trial of risperidone augmentation for refractory anxiety disorders. ( Christian, KM; Fischmann, D; Hoge, EA; Kinrys, G; Pollack, MH; Simon, NM; Worthington, JJ, 2006)
"To evaluate the efficacy and safety of risperidone in children and adults with Tourette syndrome."	9.10	A placebo-controlled trial of risperidone in Tourette syndrome. ( Katsovich, L; Leckman, JF; Peterson, BS; Scahill, L; Schultz, RT, 2003)
"Thirty patients with a primary diagnosis of an anxiety disorder-panic disorder (PD), social anxiety disorder (SAD), or generalized anxiety disorder (GAD)-refractory to initial pharmacotherapy with an adequate (or maximally tolerated) antidepressant and/or benzodiazepine trial of at least 8 weeks' duration prior to study initiation received open-label augmentation with flexibly dosed risperidone for 8 weeks."	5.12	An open-label trial of risperidone augmentation for refractory anxiety disorders. ( Christian, KM; Fischmann, D; Hoge, EA; Kinrys, G; Pollack, MH; Simon, NM; Worthington, JJ, 2006)
"To evaluate the efficacy and safety of risperidone in children and adults with Tourette syndrome."	5.10	A placebo-controlled trial of risperidone in Tourette syndrome. ( Katsovich, L; Leckman, JF; Peterson, BS; Scahill, L; Schultz, RT, 2003)

Research

Studies (3)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

"Number of Patients With Improved or Minimally Improved in Clinical Global Impression-Improvement (CGI) Scale"

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Situm, M	1
Dediol, I	1
Buljan, M	1
Živković, MV	1
Buljan, D	1
Scahill, L	1
Leckman, JF	1
Schultz, RT	1
Katsovich, L	1
Peterson, BS	1
Simon, NM	1
Hoge, EA	1
Fischmann, D	1
Worthington, JJ	1
Christian, KM	1
Kinrys, G	1
Pollack, MH	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Transcranial Magnetic Stimulation for Individuals With Tourette's Syndrome[NCT00529308]	Phase 2	20 participants (Actual)	Interventional	2007-07-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks

"Number of Patients With Much Improved or Very Much Improved on Clinical Global Impression-Improvement (CGI) Scale"

Intervention	participants (Number)
Active	2
Sham	8

Motor Cortex Excitability Normalization-Left Motor Threshold

Intervention	participants (Number)
Active	1
Sham	0

Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks

Motor Cortex Excitability Normalization-Right Motor Threshold

Intervention	µV (Mean)
Active	56.5
Sham	63.8

Yale Global Tic Severity Scale (Y-GTSS)

Intervention	µV (Mean)
Active	56
Sham	59.8

Y-GTSS is a clinician-rated scale used to assess tic severity. Motor and phonic tics are rated separately from 0 to 5 on several scales including number, frequency, intensity, complexity, and interference. Thus Motor and Phonic Tic scores can range from 0 to 25; the combined Total Tic Score ranges from 0 to 50. There is also an Impairment score that rates the overall burden due to tics. The Impairment scale yields a single score from 0 to 50 with higher scores indicating higher levels of overall impairment associated with tics. (NCT00529308)
Timeframe: 3 weeks

Article	Year
A placebo-controlled trial of risperidone in Tourette syndrome. Neurology, 2003, Apr-08, Volume: 60, Issue:7 Topics: Adolescent; Adult; Antipsychotic Agents; Body Weight; Child; Diagnostic Techniques, Neurological; Do	2003
An open-label trial of risperidone augmentation for refractory anxiety disorders. The Journal of clinical psychiatry, 2006, Volume: 67, Issue:3 Topics: Adult; Ambulatory Care; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Benzodiazepi	2006

risperidone and Claustrophobia